Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 2230 | 1.33 |
09:36 ET | 400 | 1.33 |
09:38 ET | 100 | 1.33 |
09:39 ET | 200 | 1.36 |
09:43 ET | 700 | 1.375 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 66.2M | -1.3x | --- |
Kronos Bio Inc | 64.9M | -0.5x | --- |
LAVA Therapeutics NV | 61.5M | -1.9x | --- |
BioLine RX Ltd | 55.9M | -0.9x | --- |
Dyadic International Inc | 60.8M | -6.9x | --- |
Atara Biotherapeutics Inc | 61.5M | -0.2x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $65.2M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 48.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.97 |
EPS | $-1.07 |
Book Value | $0.79 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 9.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -732.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.